Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1

Lignende værker

• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
  af: Pineda-Roman, Mauricio, et al.
  Udgivet: (2008)
• Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
  af: Barlogie, Bart, et al.
  Udgivet: (2008)
• The Arkansas approach to therapy of patients with multiple myeloma
  af: Barlogie, Bart, et al.
  Udgivet: (2007)
• TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3
  af: Shaughnessy, John D, et al.
  Udgivet: (2009)
• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
  af: Pineda-Roman, M, et al.
  Udgivet: (2008)